ストックスクリーナーアプリを入手
1.23
1.23%
0.01
前日終値:
$1.22
開ける：
$1.24
24時間の取引高:
2.41M
Relative Volume:
0.41
時価総額：
$382.04M
収益：
$160.03M
当期純損益:
$-128.58M
株価収益率:
-2.8819
EPS:
-0.4268
ネットキャッシュフロー:
$-121.21M
1週間 パフォーマンス:
+7.39%
1か月 パフォーマンス:
-20.83%
6か月 パフォーマンス:
-48.33%
1年 パフォーマンス:
+33.98%
1日の値動き範囲:
$1.19
$1.24
1週間の範囲:
$1.14
$1.285
52週間の値動き範囲:
$0.8511
$2.73
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
名前
Pacific Biosciences Of California Inc
セクター
電話
650-521-8000
住所
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.23 | 378.93M | 160.03M | -128.58M | -121.21M | -0.4268 |
ABT
Abbott Laboratories
|
86.52 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
312.28 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.02 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.91 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.11 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-06 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2024-11-11 | ダウングレード | UBS | Buy → Neutral |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-04-22 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-04-18 | ダウングレード | Goldman | Buy → Neutral |
| 2023-12-14 | 開始されました | Guggenheim | Neutral |
| 2023-12-14 | 開始されました | Stephens | Overweight |
| 2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
| 2023-11-17 | アップグレード | UBS | Neutral → Buy |
| 2023-10-31 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-06-30 | 開始されました | Goldman | Buy |
| 2023-05-10 | 開始されました | Barclays | Equal Weight |
| 2023-03-31 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | 開始されました | UBS | Neutral |
| 2023-01-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-01-21 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-01-06 | 再開されました | Piper Sandler | Neutral |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-09-27 | 開始されました | Canaccord Genuity | Buy |
| 2021-02-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-06-02 | 再開されました | Cantor Fitzgerald | Overweight |
| 2020-03-09 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-10-15 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | 開始されました | Cowen | Outperform |
| 2017-11-03 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | ダウングレード | CL King | Buy → Neutral |
| 2016-11-03 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2016-06-27 | 開始されました | CL King | Buy |
| 2016-04-15 | 開始されました | First Analysis Sec | Overweight |
| 2016-02-04 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2015-10-23 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-02-04 | 繰り返されました | Maxim Group | Buy |
| 2013-09-26 | 繰り返されました | Maxim Group | Buy |
| 2013-01-14 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Pacific Biosciences Of California Inc (PACB) 最新ニュース
AI-tuned PacBio upgrade brings sub-$300 human genomes at scale - Stock Titan
Pacific Biosciences: Pressure Is Rising (NASDAQ:PACB) - Seeking Alpha
PACB (Pacific Biosciences of California) ROC % : -47.66% (As of Mar. 2026) - GuruFocus
Q4 2025 Pacific Biosciences of California Inc Earnings Call Transcript - GuruFocus
PACB Stock Price, Quote & Chart | PACIFIC BIOSCIENCES OF CALIF (NASDAQ:PACB) - ChartMill
PacBio to Participate in the Jefferies Global Healthcare Conference - Yahoo Finance
Here's why you should add PacBio stock to your portfolio now - MSN
Pacific Biosciences of California (PACB) Stock Price, News & Analysis - MarketBeat
Pacific Biosciences of California sets $300 price point for 20x human genome sequencing on Revio - Traders Union
PACB & Blank Bio Partner to Advance RNA Foundation Models in Oncology - Yahoo Finance
PACB Secures $7.2M in Seed Funding and Partners with Blank Bio - GuruFocus
PacBio wins Basecamp Research deal for Trillion Gene Atlas initiative - MSN
Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology - BioSpace
AI lab Blank Bio raises $7.2M, teams with PacBio on tumor RNA - Stock Titan
PacBio tumbles after narrowing full-year revenue guidance - MSN
Sequencing constraints lifted as Pacific Biosciences of California enables combined genetic and methylation detection - Traders Union
PacBio expects $165M-$175M 2026 revenue as SPRQ-Nx ships later this month - MSN
Pacific Biosciences of California introduces HiFi Starter Kit to expand long-read sequencing access - Traders Union
Pacific Biosciences stock (US6932471010): Latest developments and market position - AD HOC NEWS
PACB SEC FilingsPacific Biosc 10-K, 10-Q, 8-K Forms - Stock Titan
PACB Technical Analysis | Trend, Signals & Chart Patterns | PACIFIC BIOSCIENCES OF CALIF (NASDAQ:PACB) - ChartMill
PacBio (PACB) Q1 earnings report preview: What to look for - MSN
Pacific Biosciences (PACB) Reports Q1 EPS - Insider Monkey
Pacific Biosciences of California brings global researchers together in Fukuoka - Traders Union
Why PacBio (PACB) Shares Are Getting Obliterated Today - Yahoo Finance
5 Best Penny Stocks to Buy Before They Explode - Insider Monkey
PACB Q1 Deep Dive: Consumables Growth and Clinical Adoption Offset Instrument Weakness - Yahoo Finance
Pacific Biosciences of California launches PacBioPRISM tour finale in Japan to drive HiFi innovation - Traders Union
Pacific Biosciences of California, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:PACB) 2026-05-11 - Seeking Alpha
PACB Maintained by Barclays -- Price Target Raised to $1.50 - GuruFocus
TradingKey - TradingKey
Long-read genome scan spots key variants in unexplained subfertility - Stock Titan
PacBio (PACB) Q1 2026 Earnings Call Transcript - AOL.com
Pacific Biosciences Of California (PACB) Q4 Loss Highlights Ongoing Break From Bullish Profitability Narratives - Sahm
Pacific Biosciences of California, Inc. Q1 2026 Financial Results and SEC 10-Q Filing Highlights - Minichart
[10-Q] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Quarterly Earnings Report - Stock Titan
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 1Q 2026: Revenue $37.18M, EPS ($0.03) — 10-Q Summary - TradingView
Pacific Biosciences stock (US6932471010): Flat Q1 revenue amid funding pressure in U.S. research sec - AD HOC NEWS
Pacific Biosciences (PACB) Shares Drop Following Q1 Revenue Miss - GuruFocus
Pacific Biosciences Shares Fall Amid 1Q Revenue Pressures - Moomoo
Pacific Biosciences of California, Inc. (PACB) Stock Rises on Q1 2026 Earnings - Moomoo
PACB Q1 Earnings Beat, Revenues Miss Estimates, Gross Margin Down - TradingView
Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2 - Moomoo
Pacific Biosciences Of California Inc (PACB) 財務データ
収益
当期純利益
現金流量
EPS
0.32%
0.17%
大文字化:
|
ボリューム (24 時間):